Sort by
Refine Your Search
-
with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by
-
, and scholarly activities. In partnership with Northeastern University, Alnylam Pharmaceuticals is offering a two-year Clinical Science fellowship, based in Cambridge, MA. About Alnylam Alnylam
-
prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA
-
prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA
-
clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney
-
investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy
-
of next-generation communication infrastructures. Qualifications: Ph.D. in Applied Mathematics, Electrical & Computer Engineering, Computer Science, Industrial Engineering, or a closely related field